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1. Introduction 
1.1 Tuberculosis as a global health issue and the need for reliable diagnostics in 
primary care settings  
Mycobacterium tuberculosis (Mtb) infection is one of the leading causes of morbidity and 
mortality worldwide with an estimated one third of the world’s population infected by Mtb 
resulting in about two million deaths per year (Lonnroth and Raviglione, 2008; Wallis et al., 
2010). Developing countries are burdened with the highest levels of Mtb infections and 
conversely have the lowest financial resources available to improve this situation (Figures 1 
and 2). High rates of infection are associated with poverty, low levels of public hygiene and 
often with a high prevalence of HIV+ individuals who are at particular risk of infection, all 
factors that contribute to an uncontrolled spread of Mtb infection (Corbett et al., 2006; 
Wright et al., 2009).  
Mtb can be spread from person to person via droplet nuclei that contain Mtb organisms. 
Droplet nuclei are primarily produced when people with pulmonary Mtb cough or sneeze 
and these particles can remain in the air for long periods of time. If inhaled, these droplet 
nuclei can reach the alveoli within the lungs where Mtb replicates. Individuals with Mtb 
infection can exhibit a wide range of clinical features that challenge current diagnostic 
approaches including acute active pulmonary infection with infective sputum, latent disease 
with risk of reactivation (especially in the immune-compromised host), sputum-negative 
and extrapulmonary Mtb infection and childhood tuberculosis (Wallis et al., 2010). In the 
majority of cases an infection with Mtb cannot be cleared and is contained by an effective 
immune response and the infection becomes latent and asymptomatic. About 10% of 
latently infected individuals progress to active reactivated disease during their lifetime. 
Thus individuals with latent Mtb infection act as infective foci of recurrent active disease 
and newly infect people in close contact. This large pool of undetected and untreated 
disease hampers eradication programs.  
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Fig. 1. Global Mtb burden of disease (2009). Data extracted from Global TB report 2010. 
Global efforts to control Mtb center around improving both the rate of detection of cases and 
the treatment of infective subjects as reflected in the “The Stop TB strategy” published by 
the World Health Organisation (WHO) (WHO, 2006). The strategy aims to reverse the trend 
of rising incidence, halve the 1990 prevalence and mortality due to Mtb infection by 2015 
and eliminate Mtb as a public health problem by 2050 (Maher et al., 2007). Successful 
implementation of the Stop TB strategy relies on accurate diagnostics for Mtb infection. Such 
an accurate diagnostic for Mtb infection should include the ability to identify adults and 
children with active infection, predict durable treatment success, and indicate and forecast 
reactivation of latent disease (Wallis et al., 2010). The ideal diagnostic tool would also need 
to remain trustworthy even in the setting of malnutrition and immunodeficiency and be 
performed within the primary care setting (Lucas et al., 2010). Given the enormity of the 
problem and the high prevalence in developing countries, the test(s) should also be simple 
and cheap. Despite major research efforts, a diagnostic assay or set of assays for Mtb 
infection that exhibit these properties is currently not available.  
2. Current diagnostic tools for active infection: Focus on pathogen detection 
and early immune activation 
Sputum-smear microscopy and chest radiography are still the primary tools to identify 
active Mtb infection in the typically resource-poor countries with a high-burden of Mtb 
disease (Figure 2). These tools can sometimes perform poorly and sputum is difficult to 
obtain from children. However, there are efforts to improve diagnostic assays available to 
developing countries including the development of assays that directly assay the pathogen. 
A summary of the main features of current diagnostics for active Mtb infection is given in 
Table 1. 
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Diagnosis of active tuberculosis
Platform/ 
Target 
Assays Description Disease/ 
site 
Disadvantages Advantages 
Sputum-
Smear 
Microscopy 
Conven-
tional, FM, 
LED 
Microscopic 
observation 
of stained 
acid-fast 
bacilli 
Pulmonary Sputum difficult 
to obtain from 
children, 
proportion  
of individuals 
smear negative, 
reduced 
sensitivity  
in HIV+ 
individuals 
FM 10% more 
sensitive than 
conventional 
microscopy, LED FM 
associated with low 
cost, durability and 
no need for 
darkroom  
Culture Solid, 
Liquid 
Monitor 
changes in 
media 
resources to 
detect 
bacterial 
growth 
Pulmonary Long 
turnaround  
time due to  
slow growth  
of bacteria, 
requires 
biosafety  
level  
3 facilities 
Liquid culture more 
sensitive than solid 
cultures and higher 
turnover rate 
Biochemical Adenosine 
deaminase
Detection of 
host enzyme 
released in 
response to 
intracellular 
pathogen 
Pleuritis, 
pericarditis, 
peritonitis 
  ADA levels in 
pleural, pericardial 
and ascitic  
fluid has high  
specificity and 
sensitivity for 
extrapulmonary  
Mtb infection 
Pathogen Nucleic 
acid 
amplifi-
cation tests
Detection of 
Mtb genetic 
material 
Pulmonary 
and extra-
pulmonary
Variable 
sensitivity 
especially  
in smear -ve  
and 
extrapulmonary 
disease 
High specificity and 
positive predictive 
value 
 Mtb 
antigens 
Detection of 
circulating 
Mtb antigens
Pulmonary 
and extra-
pulmonary
Variable 
sensitivity 
Quick and relatively 
easy assay to 
perform 
Serological   Detection  
of host 
humoral 
response to 
pathogen 
Active and 
latent Mtb 
disease 
Inconsistent 
estimates of 
sensitivity and 
specificity 
Fast turnaround and 
can be used for 
children 
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Diagnosis of active tuberculosis
Platform/ 
Target 
Assays Description Disease/ 
site 
Disadvantages Advantages 
Immuno-
logical 
markers 
TST Measurement
of induration 
as a result of 
exposure to 
intradermal 
tuberculin
BCG vaccinated 
subjects more 
likely to be 
positive 
Quick and relatively 
easy assay to 
perform 
 IGRAs Measurement
of interferon 
gamma 
released 
from 
lymphocytes 
when 
stimulated 
with Mtb 
antigens
Cannot 
distinguish 
between latent 
and active Mtb 
infection, 
sensitivity may 
be lower in 
HIV+ subjects 
High specificity and 
unaffected by 
previous BCG 
vaccination 
References include (Wallis et al., 2010), (Daley et al., 2007; Greco et al., 2003; Mase et al., 2007), (Dinnes 
et al., 2007), (Jiang et al., 2007), (Flores et al., 2005; Greco et al., 2006; Ling et al., 2008), (Pai et al., 2003; 
Pai et al., 2004), (Sarmiento et al., 2003; Steingart et al., 2007a; Steingart et al., 2007b; Steingart et al., 
2006a; Steingart et al., 2006b), (Pai et al., 2010), (Pai et al., 2008), (Goto et al., 2003; Kalantri et al., 2005), 
(Liang et al., 2008; Riquelme et al., 2006; Tuon et al., 2006). 
Table 1. Review of current diagnostics for Mtb infection. 
 
Fig. 2. Average gross national product ($USD) for 2009 for selected nations. Data extracted 
from Global TB report 2010 and The World Bank. 
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2.1 Pathogen detection 
2.1.1 Microscopy 
Ziehl-Neelsen sputum-smear microscopy with a conventional light microscope is commonly 
used to identify acid-fast bacilli in sputum to diagnose active Mtb infection in low and 
middle-income countries with a high prevalence of Mtb disease. This assay identifies the 
most infectious patients and is a quick and relatively easy procedure that is widely 
applicable but also requires multiple sample collections over several days (usually 3 days) 
and is dependent on the quality and bacterial load of the sputum specimen. The use of acid-
fast fluorochrome dyes with fluorescence-based microscopy (FM) is a standard assay 
performed in high-income countries to detect Mtb. FM has greater sensitivity than 
conventional microscopy and can be performed in less time but the need for a dark room 
and considerable outlay costs make it less amenable for resource poor countries. The recent 
development of light-emitting diode (LED) fluorescence microscopy may overcome some of 
the difficulties associated with the widespread implementation of FM (Cuevas et al., 2011). 
In the setting of laboratories, which contribute to a well-functioning external quality 
assurance system, revised WHO guidelines for the diagnosis of pulmonary Mtb infection 
include the reduction in the minimum number of samples that need to be tested (from three 
to two), given that the inclusion of a third sample only increases sensitivity by 2-5% (Pai et 
al., 2008). This move could significantly reduce the local collection and testing costs and 
increase the successful collection rate of samples. Furthermore, the addition of simple 
sputum processing methods (including the use of household bleach and centrifugation) can 
improve sensitivity of sputum-smear microscopy. However, it is important to remember 
that a positive acid-fast staining result may represent the presence of non-tuberculosis 
mycobacteria.  
2.1.2 Microbiological culture 
Clinical specimens suspected of containing Mtb can be inoculated onto a culture media. 
Culture of Mtb on solid media (typically egg or agar-based) is more sensitive than sputum-
smear microscopy for the diagnosis of active Mtb infection and can differentiate between 
species of mycobacteria but can take weeks to perform due to the slow growth of Mtb and 
related organisms. The sensitivity of cultures is generally between 80-85% with a specificity 
of about 98% (Prevention, 2000). The use of liquid cultures can reduce bacterial growth 
times (1-3 weeks compared to 3-8 weeks), can be automated and have sensitivity and 
specificity levels close to 100%. However, the use of such cultures requires a biosafety level 3 
environment and equipment and consumables which are relatively expensive, although 
cheaper products may become available for developing countries (WHO, 2006). 
2.1.3 Direct detection of pathogen nucleic acid 
The genus Mycobacterium consists of over 80 species and many appear similar on acid-fast 
staining; a limitation of sputum-smear microscopy. Although cultures offer some 
differentiation between species, these assays have a slow turnaround time that results in a 
delay in diagnosing Mtb infection. Amplification and detection of Mtb DNA directly from 
specimens can be an efficient and sensitive method to detect Mtb infection and may also 
allow for the detection of mutations in the Mtb genome associated with drug resistance.  
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In theory, nucleic acid amplification tests (NAATs) could identify a single mycobacterium 
at the species level but first generation NAATs were not sufficiently reliable to replace 
conventional diagnostic methods for Mtb infection (Greco et al., 2006). False negative 
results using these assays may have been due to sampling issues (given small volumes 
needed for test) and possible presence in specimens of inhibitors of the amplification 
process. False positive results may have been due to contaminations given the inherent 
increased risk in these assays due to the common amplification step. Subsequent 
improvements using internal controls (to identify assay inhibitors) and automated 
systems using a single sealed tube (reduce contamination) have improved the sensitivity 
and specificity of these assays.  
A review of several commercial NAATs showed a mean sensitivity of 96% and specificity of 
85% for smear-positive cases and 66% sensitivity and 98% specificity for smear negative 
cases (Greco et al., 2006). Importantly, these NAATs could exclude Mtb in patients with 
smear positive microscopy in which environmental mycobacteria is suspected. 
The fully automated Xpert Mtb device, which was developed by a consortium that included 
both commercial and publicly funded organisations (Cepheid Inc.; Foundation for 
Innovative New Diagnostics) has been endorsed by WHO for use in Mtb endemic countries 
(http://www.who.int/mediacentre/news/releases/2010/tb_test_20101208/en/index.html). 
The device does not require extensive staff training and produces results from the assay on 
the same day (WHO, 2006). The first assessment of the new system suggests it is highly 
sensitive for both smear positive and smear negative samples (Wallis et al., 2010) and the 
negotiation that the price per test would be reduced by 75% in countries most effected by TB 
should make this broadly accessible as an effective point-of-care diagnostic tool. 
2.1.4 Mtb antigen detection 
Assays that directly assess the presence of circulating Mtb antigens in serum, sputum, urine, 
cerebrospinal and pleural fluid to diagnose active Mtb disease are widely used. However, a 
recent review of Mtb antigen assays showed that of 47 studies examining pulmonary Mtb, 
the sensitivity of the assays varied from 2-100% and specificity varied from 33-100% (Flores 
et al., 2011). Furthermore, 21 studies examining extrapulmonary Mtb using Mtb antigen 
assays showed sensitivity levels varying from 0-100% and specificity from 62-100%. Most 
assays utilised the Mtb cell wall protein lipoarabinomannan (LAM) but some assays used 
multiple Mtb antigens. Interestingly, the detection of LAM in urine samples tended to have 
higher sensitivity in HIV+ patients than in HIV negative patients for Mtb diagnosis. 
However, much research is needed to improve the performance of these assays given the 
relative ease of translation into the primary care setting and is likely to be centred on 
identifying Mtb antigens that are abundantly expressed, specific to Mtb and resistant to the 
host’s immune response.  
2.2 Early immune activation markers 
2.2.1 Biochemical 
The diagnosis of Mtb meningitis is difficult due to the low sensitivity of identifying acid-fast 
bacilli in cerebrospinal fluid with microscopy and the length of time required for the culture 
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growth of Mtb. As an alternative, the enzyme adenosine deaminase (ADA), which is widely 
distributed in pleural, meningeal and pericardial fluids, is used in the diagnosis of Mtb 
pleuritis, pericarditis and peritonitis. The host enzyme is released from lymphocytes in 
response to infection with intracellular pathogens (Pai et al., 2010). The biochemical assay 
used to quantity ADA is quick and non-invasive. A recent systematic review of 10 studies 
involving 1364 participants showed the ADA assay exhibited a mean sensitivity of 79% and 
mean specificity of 91% for Mtb meningitis (Xu et al., 2010). However, the study stresses that 
a negative ADA assay does not rule out Mtb meningitis and should not be used alone to 
make clinical decisions regarding treatment of a patient. 
2.2.2 The potential role of early immune markers in the diagnosis of acute  
Mtb infection 
Initial pathogen recognition of Mtb by macrophages occurs via toll-like receptors (TLRs), 
resulting in the induction of transcription of pro-inflammatory cytokine genes essential to 
direct the subsequent immune response (Berrington and Hawn, 2007). Mtb ligands for TLRs 
include CpG DNA, triggering the intracellular TLR-9, and LAM and mannosylated 
phosphotidylinositol acting mainly via TLR-2 (in association with TLR-1, -4 and -6) 
(Constantoulakis et al., 2010). Once uptake into macrophages has occurred, Mtb has unique 
mechanisms to survive within the phagocytes, for example by blocking biogenesis of the 
phagolysosome. A recent study assessed mRNA expression of a combination of these innate 
markers, namely TLR-2, Coronin 1, a protein which arrests the maturation of the 
phagolysosome within macrophages, and Sp110, a protein complex important for monocyte 
differentiation and apoptosis in Mtb infection. This study revealed significantly elevated 
levels of mRNA of all three proteins in subjects with active and latent Mtb disease as 
compared to healthy uninfected subjects (Chen et al., 2010). However, larger case-controlled 
studies are needed to confirm these findings and evaluate these factors as future diagnostic 
biomarkers for Mtb infection. 
Another potential immune marker of Mtb infection is Neopterin. Neopterin is secreted 
when macrophages are activated through exposure to interferon gamma (IFN-┛) and its 
concentration in serum is increased in the early stages of infection whilst its levels decrease 
following successful treatment and increasing again upon relapse. As such it can be used as 
a non-specific pro-inflammatory marker for Mtb as its detection is also associated with other 
chronic infections that commonly coexist with Mtb, such as HIV, malaria, Hepatitis B and C 
(Fuchs et al., 1984; Immanuel et al., 2001; Turgut et al., 2006; Wallis et al., 1996).  
Other examples of innate markers that have been shown to be increased in Mtb infection are 
the soluble intercellular adhesion molecules (Walzl et al., 2008), the acute phase reactant 
proteins (Djoba Siawaya et al., 2008), soluble urokinase plasminogen activator receptor 
(Eugen-Olsen et al., 2002), CXCL10/IP10 and Pentraxin 3 (Azzurri et al., 2005), and 
procalcitonin (Baylan et al., 2006; Kandemir et al., 2003; Nyamande and Lalloo, 2006; Prat et 
al., 2006; Schleicher et al., 2005).  
Recently, an elegant study by Anne O’Garra and colleagues identified a 393-whole blood 
transcript signature for active Mtb, which correlated with clinical and radiological disease 
as well as treatment response. One of the surprising findings of this study was the 
dominant induction of genes of the IFN-┛ and type I interferon pathways in neutrophils 
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(Berry et al., 2010). This indicates the potential power of using innate responses as 
surrogate markers of Mtb infection and the strength of using a combination of markers for 
multiplex analyses. 
Despite the lack of specificity to Mtb disease associated with these innate immune 
markers, the measurement of these surrogate markers is technically straightforward and 
the assays are often readily available. It may be that by combining multiple markers 
distinct pathogen associated patterns will be described. Certainly the development of 
multiplexed assays for soluble proteins and the definition of gene expression profiles for 
Mtb disease by gene expression analysis (Jacobsen et al., 2007; Maertzdorf et al., 2010), 
such as those offered for the Luminex platform (Luminex Corp.), will continue to make 
this process more feasible.  
3. Current diagnostic tools for latent infection: Focus on immune memory 
and cytokine based diagnostics 
Overall, human T cell responses to Mtb involve CD4+, CD8+ and gamma-delta T cells. Akin 
to chronic viral infections, a broad T cell repertoire able to recognise many different types of 
bacterial epitopes (proteins as well as lipids) enhances the efficiency of the immune response 
against Mtb (Boom et al., 2003). The balance between different T helper subsets, especially 
Th1, T (Fox P3+) regulatory cells and Th17 helper cells may also be a key factor (Korn et al., 
2007; Liang et al., 2006; Marin et al., 2010; Torrado and Cooper, 2010) and could potentially 
be explored for diagnostic purposes.  
For some time, assays assessing the presence of Mtb specific memory CD8 and CD4 T cells 
have been used to identify those who previously have been infected with Mtb. Mtb-specific 
T cells are detectable within 2 – 3 weeks of acute infection in the peripheral blood and mark 
the end of the phase of rapid bacterial replication and bacterial containment. Interestingly, 
studies in mice suggest a late adaptive T cell response, which is linked to a delay in 
activation of T helper cells (Wolf et al., 2008). The measurement of Mtb specific T cells is 
therefore diagnostically insensitive in acute infection. This apparent problem may be 
overcome by the detection of Mtb-specific T cells directly at the site of infection, such as in 
fluid from broncho-alveolar lavage and cerebrospinal fluid, during early stages of disease in 
selected cohorts (Jafari et al., 2009; Thomas et al., 2008). On the other hand, the long-term 
maintenance of memory T cell responses to pathogens in peripheral blood (Semmo et al., 
2006) make the measurements of Mtb specific T cells useful as a diagnostic cross-sectional 
assay to test for prior exposure to Mtb.  
3.1 Tuberculin skin test and Interferon- release asssays (IGRA) 
One of the current well established diagnostic approaches, which is based on a T cell 
mediated delayed hypersensitivity reaction, is the tuberculin skin test (TST). The TST is 
generally performed by an intradermal injection of 5 tuberculin units using purified protein 
derivative (PPD) following the Mantoux method. The transverse diameter of the skin 
induration occuring after 48-72 hours is typically measured. Therefore at least two clinic 
visits are required for a valid test which may prove a problem. In our recent study of 
Western Australian refugee children, the TST was initiated in 341 children; however reading 
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was not possible in 37 (11%) children due to non-attendance at clinic appointments or 
absence of the child at scheduled home visits (Lucas et al., 2010). The interpretation of 
results and determination of cut-offs also varies and is infuenced by age, previous BCG 
vaccination and Mtb infection risk. In addition, this method is now recognised to have other 
limitations, such as poor specificity due to cross reactivity with both non-tuberculous 
mycobacteria and BCG (National Health Service, 2005) (Table 1). 
More recently, measurement of IFN-┛ -producing memory T cells specific for Mtb has been 
introduced into the clinical practice of many countries. Two blood-based IFN-┛ release 
assays (IGRAs) are available for diagnostic use, the Quantiferon-TB gold in-tube (QFT-GIT; 
Cellestis, Carnegie, Australia) and the T-SPOT.TB (Oxford Immunotech,Oxford, UK). Both 
assays have high specificity for adult Mtb infection including in BCG-vaccinated 
populations (Lucas et al., 2010). Both assays measure T cell IFN-┛ production in response to 
antigens encoded by the RD1 gene which is present in all strains of Mtb but is not present in 
the Mycobacterium bovis genome from which BCG is derived. This eliminates BCG cross-
reactivity, however cross-reactivity to a limited number of non-Mtb mycobacteria (M. 
kansasii, M. szulgai, M. marinum) remains. T-SPOT.TB is an enzyme-linked immunospot 
(ELISpot) assay that measures the response to two antigens, early-secreted antigenic target 6 
(ESAT-6) and culture filtrate protein 10 (CFP-10). The QFT-GIT assay is a whole blood IGRA 
assay that includes an additional Mtb-specific antigen (TB7.7). In the few head-to head 
comparisons of the latest generation tests, T-SPOT.TB and QFT-GIT both perform 
satisfactorily. Some studies however suggest that the use of the T-SPOT.TB assay may be the 
preferred option in subjects with primary and secondary (HIV, iatrogenic) 
immunodeficiencies (Lalvani, 2007; Pai et al., 2008b).  
To date, there has been limited focus on high incidence paediatric populations, which are 
at greater risk of reactivation and extrapulmonary manifestations of Mtb, including TB 
meningitis. We recently published a prospective comparative study of IGRAs and TST for 
the diagnosis of LTBI in 524 refugee children from countries with a high prevalence of 
MTb that resettled to Australia (Lucas et al., 2010). This study included 182 children <5 
years of age. In our study, the T-SPOT.TB and QFT-GIT had similar rates of positivity (8% 
and 10%, respectively) and showed good concordance when both tests gave definitive 
results (kappa= 0.78; p<0.0001). Surprisingly, both IGRAs had significant failure rates: 
15% of QFT-GIT gave indeterminate results due to failed mitogen response and 14% of T-
SPOT.TB results were inconclusive because of insufficient mononuclear leukocyte yields. 
Failure of the QFT-GIT mitogen response was associated with African ethnicity and co-
morbid infections, particularly with helminths. Overall, the TST results showed low 
concordance (about 50%) with both IGRAs. This study highlights the influence of age, 
ethnicity and clinical status on IGRA results and the limitations of using these T cell based 
tests in refugee children.  
In general, IGRAs are likely to be too complex and expensive for point-of-care testing in the 
Developing World, but their use in developed countries where the Mtb burden is much 
smaller, is currently justified. In addition, they have a role in the identification of subjects 
with latent Mtb prior to immunosuppressive therapy, including treatment with novel 
biologic drugs such as TNF- antagonists (Bellofiore et al., 2009). 
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3.2 Assessment of the role of other cytokines in Mtb infection 
As the cooperation between macrophages and T lymphocytes is critical for acute and long-
term control of Mtb, cytokines produced during their interaction, such as IL-1, IL-2, IFN-┛, 
TNF-, IL-12 and IL-23 are thought to play a critical role, all of which have potential to be 
used as surrogate markers of anti-Mtb immunity (Doherty et al., 2009). In addition, there is 
increasing evidence that during acute Mtb infection many of these pro-inflammatory 
cytokines are counteracted by induction of immune suppressive regulators (such as IL-10, 
TGF- RII, IL1-R and IDO) in addition to upregulation of intracellular molecules, e.g. IRAK-
M and suppressor of cytokine signalling (SOCS) (Almeida et al., 2009). Mtb-activated CD4+ 
T cells also release TNF- which can trigger cell lysis in infected macrophages and may kill 
intracellular Mtb (Canaday et al., 2001) and Mtb specific TNF- secreting CD4+ T cells have 
been shown to be more frequent during active than latent disease (Harari et al., 2011). In 
addition, IL- 18 from macrophages and DCs has recently been explored for its protective 
immunity against tuberculosis (Schneider et al., 2010). Newer diagnostic approaches that 
allow the measurement of mulitple cytokine simultaneously may aid in the diagnosis of 
latent infection, but also are promising tools for the identification of acute infection/re-
activation/infection of Mtb.  
3.3 Antibody responses to Mtb 
Serological blood tests detect the host’s humoral response (antibodies) to a pathogen that 
can remain circulating in the blood for several years. However, as with any pathogen 
specific immune response (antibody or T cell) this response develops after initial infection, 
and therefore its use at early infection timepoints is limited. Overall, these tests can be quick 
and inexpensive to perform using either ELISA or immunochromatographic formats. In the 
case of Mtb infection, serological assays would also be more practical for children, for whom 
sputum samples are difficult to obtain.  
It is estimated that more than a million Mtb serological tests are performed each year, 
predominantly in high disease burden countries (Steingart et al., 2011). However, many of 
these assays vary in the antigens used, source and type of antigen and the class of 
immunoglobulin investigated. First generation antibody assays used crude mixtures of Mtb 
that tended to give low specificity results; most likely due to shared antigens between 
mycobacteria species. A review to assess the efficacy of “in-house” serological assays 
showed that assays with a combination of antigens gave higher sensitivity and specificity 
than earlier assays (Steingart et al., 2009). Furthermore, assays detecting IgG and IgA anti-
Mtb antibodies gave higher sensitivity values for the detection of pulmonary Mtb than IgM-
based assays. IgM-based assays may be better suited to the detection of acute Mtb infection 
as IgM is typically expressed early in the infection but then dissipates over time.  
A recent systematic review commissioned by the WHO clearly showed that commercial 
serological assays for active Mtb infection exhibited substantial variation in sensitivity and 
specificity for pulmonary Mtb infection ((Steingart et al., 2011); Table 1). The review was 
based on 67 studies with 5,147 participants including 48% from low-middle income 
countries. Accordingly, on the 20th July 2011, WHO released a press statement warning 
against the use of serological tests for the diagnosis of active Mtb infection, stating that the 
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currently available commercial serological tests exhibit low specificity and sensitivity 
leading to misdiagnosis, mistreatment and potential harm to public health 
(http://www.who.int/mediacentre/news/releases/2011/tb_20110720n/index.html).  
The role of a protective antibody response in Mtb has been less investigated. Approximately 
90% of patients produce antibodies to Mtb proteins with antibody profiles showing great 
inter-individual variation. So far, a clear correlation between antibody profiles and disease 
status has not been clearly established, making its use for routine diagnostics problematic 
(Lyashchenko et al., 1998; Wu et al., 2010). Recently, a major contribution to the field has 
been published by Kunnath-Velayudhan and colleagues (Kunnath-Velayudhan et al., 2010). 
They screened 500 sera from suspected Mtb infected subjects against the entire Mtb 
proteome using high-throughput microarray technology and identified signatures of 
antibody responses in subjects with active Mtb, with some variation across subjects, thus 
providing novel insights into the biology of the humoral response against Mtb and 
providing further steps to develop effective humoral immunodiagnostics.  
4. Diagnosis of reactivation disease or low level pathogen detection 
Upon inhalation of Mtb, mycobacteria are phagocytosed by alveolar macrophages that recruit 
mononuclear cells to the site of infection. This leads to the characteristic granuloma formation 
consisting of macrophages, monocytes and neutrophils. At later stages, the granuloma 
becomes more organised and infiltrated by lymphocytes (Russell et al., 2010). For the majority 
of cases Mtb is contained by the immune system. How the transition between the detection 
and control of acute infection to the establishment of latent Mtb infection is mediated, remains 
unknown. A critical factor, however, is the pathogen’s ability to evade its complete elimination 
by the immune system. Studies have shown that even asymptomatic infected hosts harbour 
virulent bacteria in their tuberculous granulomas (Bouley et al., 2001; Tufariello et al., 2003). It 
is even possible that the granulomas paradoxically offer a niche for long-term survival of the 
bacteria. The barrier of activated macrophages and giant multinucleated cells that surround 
Mtb infected cells within granulomas are relatively impermeable to T cell infiltration although 
T cells remain closely associated at the site of infection (Tufariello et al., 2003). Thus 
paradoxically the combined efforts of the innate and adaptive immune response often contain 
and control the infection but fail to eliminate it. In fact the presence of Mtb antigens released 
into the host are thought to maintain the presence of an Mtb specific effector-memory 
population, which is absent in cases who have successfully eliminated the pathogen and only 
show evidence of a Mtb-specific central memory T cells (Millington et al., 2010). Ongoing 
adaptive immunity is essential in preventing reactivation of infection at a later stage (Boom et 
al., 2003). Reactivation disease occurs when latent bacteria from old, scarred granulomatous 
lesions are reactivated into an active, virulent state. A increased risk of reactivation arises 
when the host’s immune system is compromised, which may be secondarily due to immune 
suppressive drugs, especially those that modify Mtb-specific immunity such as TNF- 
antagonists, due to cancer, malnutrition or chronic viral infections, such as HIV. HIV+ 
individuals with advanced disease and low CD4+ T cell count face an approximate 10% risk 
per year of Mtb reactivation and co-infection of Mtb with HIV is now well documented (Shen 
et al., 2004). In the developing world therefore, Mtb has become one of the leading causes of 
death (Tufariello et al., 2003). This also highlights the problem that those with the greatest risk 
of reactivation are often cared for by those that are most vulnerable for Mtb infection and re-
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infection. Not surprisingly, this vicious cycle of reactivation/infection in developing countries 
has led to a flourishing Mtb spread and extensive resistance to most anti-Mtb drugs.  
To-date no reliable routine diagnostics that allow pathogen recognition at low levels or 
immune markers that predict reactivation are available. In general, the principles 
underlying the diagnosis of reactivation disease will be similar to those used for the 
detection of early acute infection; namely pathogen based assays and assays which rely on 
immune markers associated with the innate immune system (see above). In addition, there 
are reports which suggest that a change in T cell based immunity against Mtb exists in acute 
and latent infection.  
Casey et al., for example, expands the current technology of the T-SPOT.TB assay by 
measuring IFN-┛ and IL-2 responses by Mtb specific T cells after stimulation with ESAT 6 
and CFP 10 antigens, thus aiming to test T cells for polyfunctionality in active, treated and 
latent Mtb (Casey et al., 2010). The authors use a dual fluorescent ELISpot to measure two 
cytokines simultaneously, which could be adapted to routine –albeit expensive- clinical 
practice. They demonstrated that active untreated Mtb, compared to latent Mtb infection, 
was dominated by IFN-┛-only producing effector T cells. In addition, sequential testing of 
successfully treated patients revealed a shift from IFN-┛ only producing T cells to a higher 
number of effector-memory cells secreting IL-2 and IFN-┛ which confirms previous data, 
using a flowcytometric approach, by Caccamo et al (Caccamo et al., 2010).  
5. Use of genetic studies to identify novel genes involved in  
Mtb pathogenesis  
Recent technological advances has allowed the large-scale sampling of the human genome 
in a cost-effective manner and now allows researchers to examine, without a priori 
knowledge, genetic variations that may influence Mtb infection outcome. Furthermore, the 
deposit of whole genome sequences from individuals from different ethnic backgrounds 
into public databases allows a more comprehensive view of human genetic variation that 
better reflects the individuals at most risk of Mtb infection. 
Genome-wide linkage studies to identify the transfer of chromosomal regions containing 
susceptibility genes, typically using families of affected individuals, have been performed 
on Mtb (reviewed in (Moller et al., 2009)). However, of the studies to date, none of the 
linkage peaks reach genome-wide significance. The majority of these studies targeted 
different populations and not surprisingly there is no obvious overlap between highlighted 
chromosome regions for each study.  
The only reported genome-wide association study to date for Mtb involves the African TB 
Genetics consortium and the Wellcome Trust Case Control Consortium (Thye et al., 2010). In 
this study, individuals with tuberculosis and unaffected controls from the West African 
nations Ghana and The Gambia were genotyped for single nucleotide polymorphisms 
(SNPs) covering the entire genome. The initial study identified 17 loci associated with 
disease with a p<10-5. However, subsequent replication studies found that the SNP 
rs4331426 had the highest association signal (OR 1.19; total number of individuals 11,425). 
Interestingly, this SNP is located within a gene-poor region of chromosome 18 (18q11.2) but 
does contain the gene GATA6, which encodes a transcription factor known to regulate 
arachidonate 15-lipoxygenase (ALOX15); a molecule involved in regulating the release of 
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cytokines in lung epithelia cells ((Liu et al., 2009); reviewed in (Vannberg et al., 2011)). 
Although the role of this gene in Mtb susceptibility has not been clarified, it certainly 
remains a gene of interest. 
But it is important to remember that Mtb is also a variable pathogen and it is likely that 
variation in the genetics of the host and pathogen are likely to be relevant in determining 
infection outcome. 
6. Conclusion 
Microbiological detections systems are likely to remain the gold standard for detection and 
identification of extracellular pathogens aided by the increasing complementary usage of 
PCR to shorten the time and improve the accuracy of identification. Future developments 
may also include screening of other less invasive sample types including volatile samples 
from the breath, for the presence of characteristic pathogen associated molecules or 
metabolic bi-products (Phillips et al., 2007). Sensitive physical detection technologies like 
those based on mass spectrophotometry (Metzger et al., 2010) may also make their way into 
larger clinical laboratories to assist in sample analysis.  
Newly described cytokine networks such as those associated with inflammasome complexes 
(IL-1┚, IL-18, IL-33) (Church et al., 2008), the IL-23/IL-17 inflammatory pathway (Kikly et 
al., 2006) are being studied at a basic research level and are likely to contribute additional 
insights into anti-pathogen immunity. The continued development of better assays for 
established biomarkers (e.g. monokine assay; Chakera et al., 2011) to improve sensitivity 
and specificity and the speed in which results are obtained or give additional insights into 
the immune responses to the pathogen will be central to these advances. 
The complexities that underlie effective pathogen specific immunity is still incompletely 
understood and will continue to be informed by data generated using molecular approaches 
that measure changes in pathways that influence the response to infection. Advances in the 
CHIP technology (Weinmann et al., 2002), which involves the selection of specific DNA 
binding proteins by antibodies, will add additional dimension to the data being obtained 
and show which genetic levers are being pulled during a response to a given pathogen. 
Furthermore, this technology is complemented by Next-generation sequencing that will 
allow the detection of low frequency viral and host variants as well as transcripts. It is 
hoped that insights generated by such approaches, along with further iterations of these 
technologies will result in more sophisticated approaches and tools to be developed, 
affordable to the countries burdened with the highest levels of Mtb. 
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